TG 100801 NEW
| Price | $84 | $198 | $292 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-27 |
Product Details
| Product Name: TG 100801 | CAS No.: 867331-82-6 |
| Purity: 99.61% | Supply Ability: 10g |
| Release date: 2025/10/27 |
Product Introduction
Bioactivity
| Name | TG 100801 |
| Description | TG 100801 is a dual inhibitor of VEGFr2 and Src family (Src and YES) kinases and is a candidate compound for the treatment of age-related macular degeneration (AMD). |
| In vitro | TG100801 is a locally administered prodrug that readily converts to active TG100572. TG100572 inhibits endothelial cell proliferation in vitro (ED50 = 610 ± 71 nM) and blocks the phosphorylation of extracellular signal-regulated kinase (ERK) induced by VEGF [2]. |
| In vivo | TG 100801 is formed by derivatizing the phenol moiety in TG100572 to produce an ester, striking an optimal balance between stability (physical and chemical) and hydrolysis rate among the prodrugs examined. TG100801 does not exhibit meaningful kinase activity but exposure to esterases (abundant in mammalian tissues) rapidly releases active TG 100572. Mice receiving daily intraperitoneal injections of TG 100572 (5 mg/kg) display smaller CNV lesions compared to vehicle-injected mice[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 3 mg/mL (5.17 mM), Sonication is recommended. H2O : < 0.1 mg/mL (insoluble) |
| Keywords | Yes | VEGFR2 | VEGFR1 | TG-100801 | TG 100801 | Src | PDGFRβ | FGFR2 | FGFR1 |
| Inhibitors Related | Amlexanox | Sunitinib | Sorafenib | Ferulic Acid | Dasatinib | glycine | Regorafenib | Ethyl cinnamate | Formononetin | Chloramphenicol | Pazopanib | Albendazole |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Cytokine Inhibitor Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $195.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-10-27 | |
| $0.00/1kg |
VIP2Y
|
BINBO BIOLOGICAL CO.,LTD
|
2024-04-11 | |
| $84.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-10-26 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY